Replies to post #2335 on Actinium Pharmaceuticals Inc (ATNM)

[GoodGuyBill]

Thanks for that info/Link, Bluereaper. I thought I would repeat your info and add the details:

https://www.cttcanada.org/events/EventDetails.aspx?id=1396650

Speaker Biography:
Dr. Sabloff is the Clinical Director of the Ottawa Hospital Leukemia Program and the Co-Director of the Ottawa Hospital Hematology Bio-Bank. He is an associate professor of Medicine at the University of Ottawa, a member of the Blood and Marrow Transplant Program at the Ottawa Hospital and a Clinical Investigator at the Ottawa Hospital Research Institute.

He previously obtained his Bachelor and Master of Science in Biochemistry at McGill University. He completed his Medical Degree in 1995 at McGill University. He trained in Internal Medicine at Queen’s University in Kingston, Ontario. He then continued his training at the University of Ottawa in Hematology and Stem Cell Transplant.

His research is focused on studying patients with refractory acute myeloid leukemia through clinical trials, translational studies with local scientists and work in several cooperative groups both in Canada and in North America including the Center for International Blood and Marrow Transplant Research, the Myelodysplastic Consortium of Canada, the Canadian Blood and Marrow Transplant Group and the Canadian Clinical Trials Group.

Synopsis:
Refractory acute myeloid leukemia (AML) is a challenging disease with a very poor outcome. Although some novel “targeted” therapies have and are being developed none of them are curative. The only curative therapy for most types of AML, including refractory AML, is a stem cell transplant. However, this also has limited efficacy in refractory AML and is generally not well tolerated in an older population. Advances in the technology have broadened the population who are eligible for a stem cell transplant. In addition, novel techniques have improved upon the efficacy of a stem cell transplant. This presentation will highlight the challenges and describe the therapeutic advances for refractory AML with particular emphasis on applying stem cell transplants in an older population.

Learning objectives:
1. Review Acute Myeloid Leukemia - epidemiology
2. Discuss Refractory Leukemia
3. Discuss approach to Refractory Leukemia
4. Review Preliminary Midpoint Results from the Pivotal Phase 3 SIERRA Trial